The goal of these studies was to selectively release the drugs in the tumor microenvironment, exploiting the secreted cathepsin B form, which associates to the plasminogen cascade, the latter leading to the activation of factors involved in the extracellular matrix degradation and cancer cells invasion. This evidence concerns the gene PLG and neoplasm.